新兴的策略来抑制癌症治疗的G1/S过渡
Seth M Rubin1, Julien Sage2, Jan M Skotheim2
1University of California, Santa Cruz Santa Cruz United States.
Cancer research
|January 6, 2026
概括
癌症涉及不受控制的细胞生长,由细胞循环途径调节. 针对循环素依赖激酶 (CDK) 和G1/S过渡的新抑制剂为人类癌症提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞循环规则 细胞循环规则
背景情况:
- 癌症基本上是一个由分子路径失调驱动的不受控制的细胞增殖的疾病.
- 细胞周期中的G1/S相过渡是细胞分裂的关键检查点,由循环素依赖激酶 (CDK) 和视网膜母细胞瘤蛋白 (RB) 调节.
- 循环素依赖性激酶CDK4和CDK6 (CDK4/6) 与循环素D复合以酸化和抑制RB,导致E2F转录因子激活和S相进入.
研究的目的:
- 审查针对癌症治疗的G1/S阶段过渡途径的最新进展.
- 探索新型CDK抑制剂和其他途径调节剂作为单剂或组合疗法的潜力.
- 讨论除了当前的ATP竞争性CDK4/6抑制剂之外的替代策略,以反对癌症生长.
主要方法:
- 对阐明细胞循环调节的生化和遗传研究进行审查.
- 对小分子ATP竞争性CDK4/6抑制剂的开发和应用的分析.
- 检查最近开发的针对CDK和其他G1/S通路组件的抑制剂.
主要成果:
- 通过阻断G1/S转换,CDK4/6抑制剂已成为某些乳腺癌的治疗方法.
- 目前CDK4/6抑制剂的局限性需要探索替代治疗方法.
- 针对CDK和相关途径的新兴抑制剂对癌症治疗有希望.
结论:
- 针对G1/S转变是癌症治疗中验证的策略.
- 新型抑制剂有可能克服现有治疗方法的局限性.
- 涉及新的G1/S通路调节器的组合疗法可能会增强对人类癌症的疗效.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Negative Regulator Molecules
38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K


